FDA grants EUA to Pfizer’s anti - COVID pill Paxlovid | Inquirer

FDA grants EUA to Pfizer’s anti – COVID pill Paxlovid

By: - Reporter /
/ 11:59 AM March 11, 2022

FILE PHOTO: Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS

Paxlovid, a Pfizer’s coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. (Pfizer/Handout via REUTERS)

MANILA, Philippines — The Food and Drug Administration (FDA) has granted an emergency use authorization for Pfizer’s antiviral COVID-19 pill Paxlovid, officer-in-charge Oscar Gutierrez said Friday.

Apart from Paxlovid, the FDA also granted an EUA for another brand of another COVID-19 treatment pill molnupiravir.

Article continues after this advertisement

“Masaya kong binabalita na naaprubahan na namin ang paxlovid kahapon at mayroong nadagdag na isang mulnopriavir na gamot,” he said in a Laging Handa briefing.

FEATURED STORIES

(I am happy to announce that we have approved the Paxlovid yesterday and another brand of molnupiravir.)

Gutierrez said the molnupiravir brand is called Molenzavir, which is manufactured in Bangladesh.

Article continues after this advertisement

The FDA earlier granted a compassionate use permit for a generic version of Paxlovid called Bexovid.

In December last year, the FDA approved an EUA for molnupiravir. The agency has approved six other brands of the anti-COVID pill since then.

gsg/MUF
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

usa
entertainment
business
business
lifestyle
TAGS: EUA, FDA, Paxlovid

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.